Xiamen Innovax Biotech
GlaxoSmithKline Biologicals
Walvax Biotechnonology
Merck Vaccines/MSD
Serum institute of India
Nanolel
Merck Vaccines/MSD
Xiamen Innovax Biotech
China
EMA
China
FDA
India
Russian Federation
FDA
China
2019
2007
2022
2006
2022
2025
2014
2025
2021
2009
2024
2009
Not prequalified by WHO
Not prequalified by WHO
2018
Not prequalified by WHO
HPV type 16 L1 protein - 40 μg,
HPV type 18 L1 protein - 20 μg
HPV type 16 L1 protein - 20 μg,
HPV type 18 L1 protein - 20 μg
0
HPV Type 6 L1 protein - 20 μg
HPV Type 11 L1 protein - 40 μg
HPV Type 16 L1 protein - 40 μg
HPV Type 18 L1 protein - 20 μg.
0
HPV Type 6 L1 protein
HPV Type 11 L1 protein
HPV Type 16 L1 protein
HPV Type 18 L1 protein
HPV Type 6 L1 protein - 20 μg
HPV Type 11 L1 protein - 40 μg
HPV Type 16 L1 protein - 40 μg
HPV Type 18 L1 protein - 20 μg
HPV Type 31 L1 protein - 20 μg
HPV Type 33 L1 protein - 20 μg
HPV Type 45 L1 protein - 20 μg
HPV Type 52 L1 protein - 20 μg
HPV Type 58 L1 protein - 20 μg
0
Eschericia Coli
Baculovirus
Pichia Pastoris
Yeast (Saccharomyces cerevisiae)
Hansenula polymorpha
Yeast (Saccharomyces cerevisiae)
Yeast (Saccharomyces cerevisiae)
Eschericia Coli
Aluminium hydroxide
AS04 (Aluminium hydroxide and 3-deacylated monophosphoryl lipid A)
Aluminium phosphate
Aluminium hydroxiphophate Sulphate
Aluminium hydroxide
Yes (not known)
Aluminium hydroxiphophate Sulphate
Aluminium hydroxide
None
None
None
None
None
None
None
None
Not required
Not required
Not required
Not required
Not required
Not required
Not required
Not required
Liquid: Ready to use
Liquid: Ready to use
Liquid: Ready to use
Liquid: Ready to use
Liquid: Ready to use
Liquid: Ready to use
Liquid: Ready to use
Liquid: Ready to use
1-dose glass (Type 1) vial (0.5ml)
1 or 2 dose glass (type 1) vial (0.5ml/dose)
Prefilled Syringe
1-dose vial (0.5ml)
1 dose vial (0.5ml/dose)
Prefilled Syringe
1 / 2 dose glass (type 1) vial (0.5ml/dose)
1 dose vial (0.5ml/dose)
1 dose vial (0.5ml/dose)
prefilled Syringe
1-dose glass (Type 1) vial (0.5ml)
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
36 months
60 months
36 months
36 months
24 months
no information available
36 months
36 months
2-8C
2-8C
2-8C
2-8C
2-8C
2-8C
2-8C
2-8C
Type 14
Type 30
Type 14
Type 30
Type 30
no information available
None
Type 14
14.29 (carton 10 vials)
One dose vial: 57.7cm3/dose (carton 1 vial) - 11.5 (carton 10 vials) - 9.7 (carton 100 vials)
Two doses vial: 28.8 (carton 1 vial) - 5.7 (carton 10 vials) - 4.8 cm3/dose (carton 100 vials)
11.8 cm3 (carton 20 vials)
74.7 (carton 1 vial)
15 (carton 10 vials)
no information available
no information available
18.4 (carton 10 vials UNICEF)
15.11 (carton 10 vials PAHO)
(carton 10 vials)
Girls from 9 to 14 years of age: Two doses of 0.5 mL or three doses of 0.5mL.
Girls from 15 to 45 years of age: Three doses of 0.5 mL
Age 9 to and including 14 years - Two doses each of 0.5 ml.
From 15 years and above - Three doses each of 0.5 ml
Girls from 9 to 14 years of age: Two doses of 0.5 mL or three doses of 0.5mL.
Girls from 15 to 30 years of age: Three doses of 0.5 mL
Age 9 to and including 13 years - Two doses each of 0.5 ml.
From 14 years and above Three doses each of 0.5 ml
Age from 9 to 14 years: Two doses of 0.5 mL
Age 15 to 26 years of age: Three doses of 0.5 mL
Age 18 to 45: Three doses of 0.5ml
Age 9 to and including 14 years - Two doses each of 0.5 ml.
From 15 years and above Three doses each of 0.5 ml
Girls from 9 to 17 years of age: Two doses of 0.5 mL or three doses of 0.5mL.
Girls from 18 to 45 years of age: Three doses of 0.5 mL
no information available
There are no safety, immunogenicity or efficacy data to support interchangeability of Cervarix with
other HPV vaccines.
no information available
There are no safety, immunogenicity or efficacy data to support change during vaccination with
Gardasil to other HPV vaccines which do not cover the same HPV types.
It is recommended that individuals who receive a first dose of CERVAVAC® complete the vaccination course with CERVAVAC
no information available
Studies using a mixed regimen (interchangeability) of HPV vaccines were not performed for Gardasil 9.
no information available
not required
Not required
Not required
Not required
Not required
Not required
Not required
Not required
no information available
Cervarix is not recommended for use in children below 9 years of age due to limited data on safety
and immunogenicity in this age-group.
no information available
The safety and efficacy of Gardasil in children below 9 years of age have not been established. No data are available.
The safety and efficacy of CERVAVAC® in children below 9 years of age have not been established. No data are available.
no information available
The safety and efficacy of Gardasil9 in children below 9 years of age have not been established. No data are available
no information available
YES
YES
YES
YES
NO
NO
YES
NO
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025
1. World Health Organization (2023). Prequalified vaccines [online database]. Geneva: WHO (https://extranet.who.int/prequal/vaccines/prequalified-vaccines, accessed 19 June 2025).
1. European Medicines Agency (n.d.). Cervarix: EU summary of product characteristics [product information document]. Amsterdam: EMA (https://www.ema.europa.eu/en/documents/product-information/cervarix-epa…, accessed 19 June 2025).
1. World Health Organization (2023). Prequalified vaccines [online database]. Geneva: WHO (https://extranet.who.int/prequal/vaccines/prequalified-vaccines, accessed 19 June 2025).
1. European Medicines Agency (n.d.). Gardasil: EU summary of product characteristics [product information document]. Amsterdam: EMA (https://www.ema.europa.eu/en/documents/product-information/gardasil-epa…, accessed 19 June 2025).
1. Serum Institute of India (2025). Cervavac [website]. Pune: Serum Institute of India (https://www.seruminstitute.com/product_ind_cervavac.php, accessed 19 June 2025).
1. Nanolek website (2025) https://nanolek.ru/en/news/companynews/nanolek-received-a-registration-… (accessed on 1 July 2025)
1. European Medicines Agency (n.d.). Gardasil 9: EU summary of product characteristics [product information document]. Amsterdam: EMA (https://www.ema.europa.eu/en/documents/product-information/gardasil-9-e…, accessed 19 June 2025).
1. Xinhua News Agency (2025). China approves new domestically developed HPV vaccine. [website]. (https://english.news.cn/20250530/3c129f096e0842b2a2d4e43f82a190ca/c.html, accessed 19 June 2025).
2. Hu Y-M, Zhang X, Li Q, Wang J, Chen Y, Liu Z, et al. (2023). Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial. Sci Bull (Beijing). 68:2448–2455.
